renal cell carcinoma
Conditions
Interventions
Immunotherapy combination group:NA
Sponsors
Zhejiang Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old, gender not limited; 2. Postoperative pathology confirmed renal cell carcinoma (RCC), with a high WHO/ISUP grade or high recurrence risk factors such as tumor vascular invasion, renal vein/inferior vena cava tumor thrombus, T3 or above pathological stage, and tumor necrosis. 3. Those who have completed radical or partial nephrectomy and are evaluated as suitable for immunotherapy after the operation; 4. The ECOG physical condition score is 0 to 1 point. 5. After the operation, complete clinical assessment data were available, including preoperative/postoperative imaging examinations (enhanced CT MRI), laboratory indicators (renal function, immune-related indicators, etc.), and tumor tissue samples. 6. Expected survival time >= 12 months, with good organ function reserve; 7. The patient voluntarily signed the informed consent form and was willing to cooperate with the relevant follow-up and assessment of the research.
Exclusion criteria
Exclusion criteria: 1. Histological types of non-renal cell carcinoma (such as urothelial carcinoma, metastatic carcinoma, etc.); 2. Have received systemic anti-tumor treatment before or after the operation, including but not limited to immune checkpoint suppressants, targeted therapy or cell therapy; 3. There is an active autoimmune disease or the need for long-term use of immunosuppressants (such as glucocorticoids > 10mg/ day prednisone or equivalent doses); 4. Combined with severe infections (such as HIV, active hepatitis B/C) or a state of weakened immune function; 5. There are severe cardiovascular diseases (such as heart failure, arrhythmia), lung diseases (such as interstitial lung disease), liver and kidney failure, etc., which cannot tolerate immunotherapy. 6. Pregnant or lactating women, or those planning to become pregnant during the study period; 7. Combined with other malignant tumors, or having a history of other tumors within 5 years (certain skin cancers, cervical cancer in situ, etc. may be included as appropriate); 8. Patients with mental illness or cognitive impairment, which affects the exercise of their right to know or their compliance with research;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate;Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment-related adverse events and immune-related adverse events;Objective response rate; | — |
Countries
China
Contacts
Public ContactQi Zhang
Zhejiang Provincial People's Hospital
Outcome results
None listed